Amgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application Read more about Amgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application
Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting Read more about Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting
Amgen's First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion Read more about Amgen's First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
Amgen's Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion Read more about Amgen's Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
Amgen Announces Webcast of 2011 Second Quarter Financial Results Read more about Amgen Announces Webcast of 2011 Second Quarter Financial Results
Amgen Resolves G-CSF Patent Litigation With Teva Read more about Amgen Resolves G-CSF Patent Litigation With Teva
XGEVA® (Denosumab) Granted Marketing Authorization in the European Union Read more about XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss Read more about Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss
Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence Read more about Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence
Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone Read more about Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
